创新药ETF国泰（517110）盘中领涨超2.5%，集采政策迎来边际改善，短期关注估值修复

Group 1 - The National Healthcare Security Administration emphasized principles of "stabilizing clinical practices, ensuring quality, preventing collusion, and countering internal competition" during a recent press conference, indicating an optimization of procurement rules regarding quantity and price, moving away from a simple lowest price reference [1] - With the optimization of procurement rules, competition in procurement prices is expected to improve, suggesting short-term investment opportunities in segments with relatively favorable competitive landscapes [1] - Current market focus is on the performance of mid-year reports and the 2025 National Medical Insurance Catalog negotiations, with particular attention on the innovative drug sector [1] Group 2 - The Guotai Innovation Drug ETF (517110) tracks the SHS Innovation Drug Index (931409), which selects securities from the Shanghai, Shenzhen, and Hong Kong markets involved in the research, production, and sales of innovative drugs, focusing on companies with high R&D investment and good growth potential [1] - Investors without stock accounts may consider the Guotai CSI Hong Kong-Shenzhen Innovation Drug Industry ETF Initiation Link A (014117) and Link C (014118) [1]